Molindone: Difference between revisions

	WikiDoc Resources for Molindone
Articles
Most recent articles on Molindone Most cited articles on Molindone Review articles on Molindone Articles on Molindone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Molindone Images of Molindone Photos of Molindone Podcasts & MP3s on Molindone Videos on Molindone
Evidence Based Medicine
Cochrane Collaboration on Molindone Bandolier on Molindone TRIP on Molindone
Clinical Trials
Ongoing Trials on Molindone at Clinical Trials.gov Trial results on Molindone Clinical Trials on Molindone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Molindone NICE Guidance on Molindone NHS PRODIGY Guidance FDA on Molindone CDC on Molindone
Books
Books on Molindone
News
Molindone in the news Be alerted to news on Molindone News trends on Molindone
Commentary
Blogs on Molindone
Definitions
Definitions of Molindone
Patient Resources / Community
Patient resources on Molindone Discussion groups on Molindone Patient Handouts on Molindone Directions to Hospitals Treating Molindone Risk calculators and risk factors for Molindone
Healthcare Provider Resources
Symptoms of Molindone Causes & Risk Factors for Molindone Diagnostic studies for Molindone Treatment of Molindone
Continuing Medical Education (CME)
CME Programs on Molindone
International
Molindone en Espanol Molindone en Francais
Business
Molindone in the Marketplace Patents on Molindone
Experimental / Informatics
List of terms related to Molindone

Molindone
Clinical data
Trade names	Moban
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a682238
Pregnancy; category	C;
Routes of; administration	Oral
ATC code	N05AE02 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Metabolism	Hepatic
Elimination half-life	1.5 hours
Excretion	Minor, renal and fecal
Identifiers
	IUPAC name 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-; 1,5,6,7-tetrahydro-4H-indol-4-one;
CAS Number	7416-34-4 ;
PubChem CID	23897;
IUPHAR/BPS	207;
DrugBank	DB01618 ;
ChemSpider	22342 ;
UNII	RT3Y3QMF8N;
KEGG	D08226 ;
ChEMBL	ChEMBL460 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C16H24N2O2
Molar mass	276.374 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C2c1c(c(nc1CCC2CN3CCOCC3)C)CC;
	InChI InChI=1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3 ; Key:KLPWJLBORRMFGK-UHFFFAOYSA-N ;
(what is this?) (verify)

VisualWikitext

Latest revision as of 16:34, 13 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Molindone (Moban) is a therapeutic antipsychotic, used in the treatment of schizophrenia.^[1] It works by blocking the effects of dopamine in the brain, leading to diminished psychoses. It is rapidly absorbed when taken orally.

It is sometimes described as a typical antipsychotic,^[2] and sometimes described as an atypical antipsychotic.^[3]

Molindone was discontinued by its sole supplier, Endo Pharmaceuticals, on January 13, 2010. ^[4]

Adverse effects

The side effect profile of molindone is similar to that of other typical antipsychotics. Unlike most antipsychotics, however, molindone use is associated with weight loss.^[3]^[5]

References

↑ "molindone". F.A. Davis Company.
↑ Aparasu RR, Jano E, Johnson ML, Chen H (October 2008). "Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients". Am J Geriatr Pharmacother. 6 (4): 198–204. doi:10.1016/j.amjopharm.2008.10.003. PMID 19028375.
↑ ^3.0 ^3.1 Bagnall A, Fenton M, Kleijnen J, Lewis R (2007). Bagnall, Anne-Marie, ed. "Molindone for schizophrenia and severe mental illness". Cochrane Database Syst Rev (1): CD002083. doi:10.1002/14651858.CD002083.pub2. PMID 17253473.
↑ http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050794.htm
↑ Allison DB; Mentore JL; Heo M; et al. (1999). "Antipsychotic-induced weight gain: a comprehensive research synthesis". Am J Psychiatry. 156 (11): 1686–96. PMID 10553730. Unknown parameter |author-separator= ignored (help) Free full text

[1] "molindone". F.A. Davis Company.

[pmid19028375-2] Aparasu RR, Jano E, Johnson ML, Chen H (October 2008). "Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients". Am J Geriatr Pharmacother. 6 (4): 198–204. doi:10.1016/j.amjopharm.2008.10.003. PMID 19028375.

[pmid17253473-3] 3.0 ^3.1 Bagnall A, Fenton M, Kleijnen J, Lewis R (2007). Bagnall, Anne-Marie, ed. "Molindone for schizophrenia and severe mental illness". Cochrane Database Syst Rev (1): CD002083. doi:10.1002/14651858.CD002083.pub2. PMID 17253473.

[FDA-4] ttp://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050794.htm

[5] Allison DB; Mentore JL; Heo M; et al. (1999). "Antipsychotic-induced weight gain: a comprehensive research synthesis". Am J Psychiatry. 156 (11): 1686–96. PMID 10553730. Unknown parameter |author-separator= ignored (help) Free full text

[1]

[2]

[3]

[4]

[5]

@@ Line 1: / Line 1: @@
-'''Molindone''' is a therapeutic [[antipsychotic]], used in the treatment of [[schizophrenia]]. <ref>{{cite web
+{{Drugbox
-  | last =
+| Verifiedfields = changed
-  | first =
+| verifiedrevid = 408764754
-  | authorlink =
+| IUPAC_name = 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-<br>1,5,6,7-tetrahydro-4''H''-indol-4-one
-  | coauthors =
+| image = Mlindone Wiki Str.png
-  | title = molindone
-  | work =
-  | publisher = F.A. Davis Company
-  | date =
-  | url = http://www.drugguide.com/monograph_library/psychotropic_drugs/molindone.htm
-  | format = web
-  | doi =
-  | accessdate = January 21, 2007 }}</ref> It works by blocking the effects of [[dopamine]] in the brain, leading to diminished psychoses.  It is rapidly absorbed when taken by mouth.
-<!--  Commented out because image was deleted: [[Image:MobanAd.png|thumb|300px|left|Advertisement, 1982.]] -->
-==Side Effects==
-{{see|Typical antipsychotic}}
-==See also==
-*[[Typical antipsychotic]]
-==References==
+<!--Clinical data-->
-<references/>
+| tradename = Moban
+| Drugs.com = {{drugs.com|CDI|molindone}}
+| MedlinePlus = a682238
+| pregnancy_category = C
+| legal_status = Rx-only
+| routes_of_administration = Oral
-{{Antipsychotics}}
+<!--Pharmacokinetic data-->
+| bioavailability =
+| protein_bound =
+| metabolism = [[Liver|Hepatic]]
+| elimination_half-life = 1.5 hours
+| excretion = Minor, [[kidney|renal]] and fecal
+<!--Identifiers-->
+| CASNo_Ref = {{cascite|correct|CAS}}
+| CAS_number_Ref = {{cascite|correct|??}}
+| CAS_number = 7416-34-4
+| ATC_prefix = N05
+| ATC_suffix = AE02
+| PubChem = 23897
+| IUPHAR_ligand = 207
+| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
+| DrugBank = DB01618
+| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
+| ChemSpiderID = 22342
+| UNII_Ref = {{fdacite|correct|FDA}}
+| UNII = RT3Y3QMF8N
+| KEGG_Ref = {{keggcite|correct|kegg}}
+| KEGG = D08226
+| ChEMBL_Ref = {{ebicite|correct|EBI}}
+| ChEMBL = 460
+<!--Chemical data-->
+| C=16 | H=24 | N=2 | O=2
+| molecular_weight = 276.374 g/mol
+| smiles = O=C2c1c(c(nc1CCC2CN3CCOCC3)C)CC
+| InChI = 1/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3
+| InChIKey = KLPWJLBORRMFGK-UHFFFAOYAN
+| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
+| StdInChI = 1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3
+| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
+| StdInChIKey = KLPWJLBORRMFGK-UHFFFAOYSA-N
+}}
+__NOTOC__
+{{SI}}
+{{CMG}}
+== Overview ==
+'''Molindone''' ('''Moban''') is a therapeutic [[antipsychotic]], used in the treatment of [[schizophrenia]].<ref>{{cite web | title = molindone | publisher = F.A. Davis Company | url = http://www.drugguide.com/monograph_library/psychotropic_drugs/molindone.htm}}</ref> It works by blocking the effects of [[dopamine]] in the brain, leading to diminished psychoses.  It is rapidly absorbed when taken orally.
+It is sometimes described as a [[typical antipsychotic]],<ref name="pmid19028375">{{cite journal |author=Aparasu RR, Jano E, Johnson ML, Chen H |title=Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients |journal=Am J Geriatr Pharmacother |volume=6 |issue=4 |pages=198–204 |date=October 2008 |pmid=19028375 |doi=10.1016/j.amjopharm.2008.10.003 |url=http://linkinghub.elsevier.com/retrieve/pii/S1543-5946(08)00055-X}}</ref> and sometimes described as an [[atypical antipsychotic]].<ref name="pmid17253473">{{cite journal |author=Bagnall A, Fenton M, Kleijnen J, Lewis R |title=Molindone for schizophrenia and severe mental illness |journal=Cochrane Database Syst Rev |volume= |issue=1 |pages=CD002083 |year=2007 |pmid=17253473 |doi=10.1002/14651858.CD002083.pub2 |editor1-last=Bagnall |editor1-first=Anne-Marie}}</ref>
+Molindone was discontinued by its sole supplier, Endo Pharmaceuticals, on January 13, 2010.  <ref name="FDA">http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050794.htm</ref>
+== Adverse effects ==
+{{main|Typical antipsychotic}}
+The side effect profile of molindone is similar to that of other typical antipsychotics. Unlike most antipsychotics, however, molindone use is associated with weight loss.<ref name="pmid17253473"/><ref>{{cite journal |author=Allison DB |title=Antipsychotic-induced weight gain: a comprehensive research synthesis |journal=[[American Journal of Psychiatry|Am J Psychiatry]] |volume=156 |issue=11 |pages=1686–96 |year=1999 |pmid=10553730 |doi= |author-separator=, |author2=Mentore JL |author3=Heo M |display-authors=3 |last4=Chandler |first4=LP |last5=Cappelleri |first5=JC |last6=Infante |first6=MC |last7=Weiden |first7=PJ}} [http://ajp.psychiatryonline.org/doi/abs/10.1176/ajp.156.11.1686 Free full text]</ref>
+== See also ==
+* [[Losindole]]
+* [[Piquindone]]
-{{psychoactive-stub}}
+== References ==
+{{Reflist|2}}
-[[Category:Typical antipsychotics]]
+{{Antipsychotics}}
+{{Dopaminergics}}
-[[sv:Molidon]
+[[Category:drug]]
-{{WikiDoc Sources}}
+[[Category:Morpholines]]
+[[Category:Indoles]]
+[[Category:Ketones]]
+[[Category:Atypical antipsychotics]]

v t e Antipsychotics (neuroleptics) (N05A)
Typical	Benzamides: Levosulpiride • Nemonapride • Sulpiride • Sultopride • Tiapride • Veralipride; Butyrophenones: Azaperone • Benperidol • Bromperidol • Droperidol • Fluanisone • Haloperidol • Lenperone • Moperone • Pipamperone • Spiperone • Timiperone • Trifluperidol; Diphenylbutylpiperidines: Clopimozide • Fluspirilene • Penfluridol • Pimozide; Phenothiazines: Acepromazine • Acetophenazine • Butaperazine • Carphenazine • Chloracizine • Chlorproethazine • Chlorpromazine • Cyamemazine • Dixyrazine • Fluacizine • Fluphenazine • Levomepromazine/Methotrimeprazine • Mesoridazine • Perazine • Periciazine • Perphenazine • Piperacetazine • Pipotiazine • Prochlorperazine • Promazine • Promethazine • Propiomazine • Sulforidazine • Thiethylperazine • Thiopropazate • Thioproperazine • Thioridazine • Trifluoperazine • Triflupromazine; Thioxanthenes: Chlorprothixene • Clopenthixol • Flupentixol • Thiothixene • Zuclopenthixol; Tricyclics: Amoxapine • Butaclamol • Fluotracen • Loxapine • Metitepine/Methiothepin • Octoclothiepin • Trimipramine; Others: Prothipendyl
Atypical	Benzamides: Amisulpride • Remoxipride; Butyrophenones: Cinuperone • Setoperone; Benzo(iso)oxazole piperidines: Iloperidone • Ocaperidone • Paliperidone • Risperidone; Benzo(iso)thiazole piperazines: Lurasidone • Perospirone • Revospirone • Tiospirone • Ziprasidone; Diphenylbutylpiperazines: Amperozide; Phenylpiperazines: Aripiprazole • Bifeprunox • Elopiprazole • Umespirone; Tricyclics: Asenapine • Carpipramine • Clocapramine • Clotiapine • Clozapine • Fluperlapine • Gevotroline • Metitepine/Methiothepin • Mosapramine • NDMC • Olanzapine • Piquindone • Quetiapine • Tenilapine • Zotepine; Others: Blonanserin • Cariprazine • Molindone • Pimavanserin • Roxindole • Sarizotan • Sertindole • Spiramide
Others	Azacyclonol • Cannabidiol • D-Cycloserine • Lithium • Mifepristone • Oxypertine • Reserpine • Rimcazole • Secretin • Talnetant • Tetrabenazine • Vabicaserin
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III Template:Psychology navs

Molindone: Difference between revisions

Latest revision as of 16:34, 13 April 2015

Overview

Adverse effects

See also

References

Navigation menu

Search